Download article

DOI: https://doi.org/10.22263/2312-4156.2022.2.25

Dikareva E.A.¹, Pimanov S.I.¹, Makarenko E.V.¹, Lahutchau V.V.¹, Kukharau A.V.²
Adherence to therapy in rheumatology practice. Literature review
¹Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
²Vitebsk Regional Clinical Hospital, Vitebsk, Republic of Belarus

Vestnik VGMU. 2022;21(2):25-34.

Abstract.
The problem of adherence to therapy continues to be one of the most significant for modern medicine. The aim of the work was to analyze the literature data on adherence to therapy in rheumatological practice. Currently, various definitions of adherence to therapy are used: «compliance», «adherence», «concordance». Despite significant progress in the creation of new highly effective pathogenetic drugs in rheumatology, the effectiveness of the prescribed therapy remains insufficiently satisfactory. Often this situation is associated with low adherence to treatment. In the treatment of rheumatoid arthritis with disease modifying drugs, adherence made up about 65%. In osteoarthritis, there was a decrease in adherence not only to drug therapy, but also to other methods of conservative treatment. An increase in fracture risk by 16% was found in those osteoporotic patients who had poor adherence to treatment. When treated with non-steroidal anti-inflammatory drugs, the risk of adverse events from the upper gastrointestinal tract in patients with low adherence to therapy with proton pump inhibitors increased 4.0 times. The rate of progression of the disease, the degree of functional disorders and the level of patients’ life quality depend on the level of adherence to treatment.
Key words: adherence to therapy, rheumatoid arthritis, osteoarthritis, osteoporosis, proton pump inhibitors, compliance.

References

1. Kelly A, Tong A, Tymms K, March L, Craig JC, De Vera M, et al. Outcome measures in rheumatology - interventions for medication adherence (OMERACT-Adherence) core domain set for trials of interventions for medication adherence in rheumatology: 5 phase study protocol. Trial. 2018;19(1). Avaiable from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870260/pdf/13063_2018_Article_2565.pdf. [Accessed 05th May 2022].
2. Van den Bemt BJF, Zwikker HE, van Den Ende CHM. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol. 2012 May;8(4):337-51. doi: http://dx.doi.org/10.1586/eci.12.23
3. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014 Mar;73(3):492-509. doi: http://dx.doi.org/10.1136/annrheumdis-2013-204573
4. World Health Organization; Sabaté E, ‎ed. Adherence to long-term therapies: evidence for action. Geneva; 2003. Avaiable from: https://apps.who.int/iris/handle/10665/42682. [Accessed 05th May 2022].
5. Horne R, John B, Barber N, Elliott R, Morgan M, Cribb A, et al. Concordance, adherence and compliance in medicine taking : Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO). 2005. Avaiable from: https://njl-admin.nihr.ac.uk/document/download/2027234. [Accessed 06th May 2022].
6. Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging. 2004;21(12):793-811. doi: http://dx.doi.org/10.2165/00002512-200421120-00004
7. Pasma A, Schenk CV, Timman R, Busschbach JJV, van den Bemt BJF, Molenaar E, et al. Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease. Arthritis Res Ther. 2015 Oct;17:281. doi: http://dx.doi.org/10.1186/s13075-015-0801-4
8. Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010 Apr;69(4):631-7. doi: http://dx.doi.org/10.1136/ard.2009.123919
9. Jahng KH, Martin LR, Golin CE, DiMatteo MR. Preferences for medical collaboration: patient-physician congruence and patient outcomes. Patient Educ Couns. 2005 Jun;57(3):308-14. doi: http://dx.doi.org/10.1016/j.pec.2004.08.006
10. Shahouri SH, Michaud K, Mikuls TR, Caplan L, Shaver TS, Anderson JD, et al. Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism. Arthritis Rheum. 2011 Nov;63(11):3204-15. doi: http://dx.doi.org/10.1002/art.30524
11. Combe B, Logeart I, Belkacemi MC, Dadoun S, Schaeverbeke T, Daurès JP, et al. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort. Ann Rheum Dis. 2015 Apr;74(4):724-9. doi: http://dx.doi.org/10.1136/annrheumdis-2013-204178
12. Salt E, Frazier SK. Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature. Orthop Nurs. 2010 Jul-Aug;29(4):260-75. doi: http://dx.doi.org/10.1097/NOR.0b013e3181e5c2c9
13. Contreras-Yáñez I, De León SP, Cabiedes J, Rull-Gabayet M, Pascual-Ramos V. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci. 2010 Oct;340(4):282-90. doi: http://dx.doi.org/10.1097/MAJ.0b013e3181e8bcb0
14. Cannon GW, Mikuls TR, Hayden CL, Ying J, Curtis JR, Reimold AM, et al. Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. Arthritis Care Res (Hoboken). 2011 Dec;63(12):1680-90. doi: http://dx.doi.org/10.1002/acr.20629
15. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: http://dx.doi.org/10.1002/acr.21641
16. Waimann CA, Marengo MF, de Achaval S, Cox VL, Garcia-Gonzalez A, Reveille JD, et al. Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis. consequences of low adherence. Arthritis Rheum. 2013 Jun;65(6):1421-9. doi: http://dx.doi.org/10.1002/art.37917
17. Akhunova RR, Iakhin KK, Iakupova SP, Salikhov IG. Adherence of rheumatoid arthritis patients to treatment with basic anti-inflammatory drugs. Klinitsist. 2012;6(1):42-5. (In Russ.)
18. Wang J, Yang L, Li Q, Wu Z, Sun Y, Zou Q, et al. Construction of an adherence rating scale for exercise therapy for patients with knee osteoarthritis. BMC Musculoskelet Disord. 2018 Jul;19(1):263. doi: http://dx.doi.org/10.1186/s12891-018-2200-x
19. Sharapova EP, Alekseeva LI, Taskina EA, Kashevarova NG, Anikin SG, Korotkova TA, i dr. Efficacy and Safety of Alflutop in the Treatment of Patients with Osteoarthritis of the Knee: A Multicenter, Open-Label, Randomized Clinical Trial. Farmateka. 2020;27(13):87-95. (In Russ.)
20. Cleveland RJ, Nelson AE, Callahan LF. Knee and hip osteoarthritis as predictors of premature death: a review of the evidence. Clin Exp Rheumatol. 2019 Sep-Oct;37 Suppl 120(5):24-30.
21. Akhverdian IuR, Sivordova LE, Poliakova IuV, Zavodovskii BV, Papichev EV, Pavlovskaia VN. Long-term use of unsaponifiable soy and avocado compounds in osteoarthritis in real clinical practice. V: Sborovskaia IA, red. Aktual'nye problemy sovremennoi revmatologii: sb nauch rabot. Moskva, RF: Planeta; 2019. Vyp 36. Р. 146-55. (In Russ.)
22. Maksimov DM. Assessment of adherence in patients with osteoarthritis (osteoarthritis) by different methods of conservative treatment. Revmatologiia. 2009;56(2):45-9. (In Russ.)
23. González-Arellano JA, Milla-Villeda RH, Hernández-Vera GE, Cisneros-Pérez V, Lazalde B, Reyes M. Prevalence of osteoporosis and osteopenia among women over fifty years of age, from the city of Durango, Mexico, diagnosed by forearm-DEXA. Gac Med Mex. 2007 Sep-Oct;143(5):365-9.
24. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005 Sep;21(9):1453-60. doi: http://dx.doi.org/10.1185/030079905X61875
25. Delmas PD, Vrijens B, Eastell R, Roux C, Pols HAP, Ringe JD, et al. Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2007 Apr;92(4):1296-304. doi: http://dx.doi.org/10.1210/jc.2006-1526
26. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 2003 Dec;14(12):965-8. doi: http://dx.doi.org/10.1007/s00198-003-1502-4
27. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004 Dec;15(12):1003-8. doi: http://dx.doi.org/10.1007/s00198-004-1652-z
28. Dikareva EA, Makarenko EV, Pimanov SI. Risk Assessment of Gastropathy Induced by Nonsteroidal Anti-inflammatory Drugs Based on International Consensus Documents. Vestn VGMU. 2015;14(5):39-45. (In Russ.)
29. Dikareva EA, Voropaeva AV, Makarenko EV, Pimanov SI. Significance of Helicobacter pylori genes in the development of gastropathy induced by nonsteroidal anti-inflammatory drugs. Problemy Zdorov'ia Ekologii. 2015;(2):37-41. (In Russ.)
30. Dikareva EA, Matveenko ME, Pimanov SI, Makarenko EV. Clinical, endoscopic, and morphological effects of Helicobacter pylori eradication in patients with long-term use of nonsteroidal anti-inflammatory drugs. Vestn VGMU. 2014;13(5):52-9. (In Russ.)
31. Pimanov SI, Semenova EV, Makarenko EV, Ruselik EA. Gastroduodenal ulcers caused by antiaggregant and nonsteroidal anti-inflammatory drugs: prevention according to new guidelines. Consilium medicum. Gastroenterologiia. 2009;11(8):13-20. (In Russ.)
32. Pimanov SI, Makarenko EV, Dikareva EA. Antisecretory therapy: compelling benefits and potential risks. Med Sovet. 2018;(3):26-31. (In Russ.)
33. Pimanov SI, Makarenko EV, Ruselik EA. Pharmacotherapy of acid-dependent diseases: proven truths and new recommendations. Med Sovet. 2012;(3):22-8. (In Russ.)
34. Pimanov SI, Makarenko EV, Dikareva EA. Adherence to proton pump inhibitor therapy with continuous use of nonsteroidal anti-inflammatory drugs. Terapevt Arkh. 2015;87(4):58-61. (In Russ.)
35. Goldstein JL, Howard KB, Walton SM, McLaughlin TP, Kruzikas DT. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer events. Clin Gastroenterol Hepatol. 2006 Nov;4(11):1337-45. doi: http://dx.doi.org/10.1016/j.cgh.2006.08.016
36. Henriksson K, From J, Stratelis G. Patient-reported adherence to coprescribed proton pump inhibitor gastroprotection in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis patients using nonsteroidal anti-inflammatory drugs. Patient Prefer Adherence. 2014 Nov;8:1611-7. doi: http://dx.doi.org/10.2147/PPA.S70651
37. van Soest EM, Valkhoff VE, Mazzaglia G, Schade R, Molokhia M, Goldstein JL, et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut. 2011 Dec;60(12):1650-9. doi: http://dx.doi.org/10.1136/gut.2011.239848
38. van Soest EM, Sturkenboom MCJM, Dieleman JP, Verhamme KMC, Siersema PD, Kuipers EJ. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther. 2007 Jul;26(2):265-75. doi: http://dx.doi.org/10.1111/j.1365-2036.2007.03358.x
39. Sturkenboom MCJM, Burke TA, Tangelder MJD, Dieleman JP, Walton S, Goldstein JL. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2003 Dec;18(11-12):1137-47. doi: http://dx.doi.org/10.1046/j.1365-2036.2003.01795.x
40. Valkhoff VE, van Soest EM, Mazzaglia G, Molokhia M, Schade R, Trifiro G, et al. Adherence to gastroprotection during cyclooxygenase 2 inhibitor treatment and the risk of upper gastrointestinal tract events: a population-based study. Arthritis Rheum. 2012 Aug;64(8):2792-802. doi: http://dx.doi.org/10.1002/art.34433
41. Jonasson C, Hatlebakk JG, Lundell L, Kouri JP, Andersen M, Granath F. Association between adherence to concomitant proton pump inhibitor therapy in current NSAID users and upper gastrointestinal complications. Eur J Gastroenterol Hepatol. 2013 May;25(5):531-8. doi: http://dx.doi.org/10.1097/MEG.0b013e32835d5acd
42. Pimanov SI, Dikareva EA, Makarenko EV. Commitment to pharmacotherapy is a prerequisite for effective treatment. Lecheb Delo. 2014;(5):47-52. (In Russ.)

Information about authors:
Dikareva E.A. – Candidate of Medical Sciences, associate professor of the Chair of Internal Diseases & Ultrasound Diagnostics of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University;
Pimanov S.I. – Doctor of Medical Sciences, professor, head of the Chair of Internal Diseases & Ultrasound Diagnostics of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University;
Makarenko E.V. – Doctor of Medical Sciences, professor of the Chair of Internal Diseases & Ultrasound Diagnostics of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University;
Lahutchau V.V. – Candidate of Medical Sciences, associate professor of the Chair of Internal Diseases & Ultrasound Diagnostics of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University;
Kukharau A.V. – endoscopist, Vitebsk Regional Clinical Hospital.

Correspondence address: Republic of Belarus, 210009, Vitebsk, 27 Frunze ave., Vitebsk State Order of Peoples’ Friendship Medical University, Chair of Internal Diseases & Ultrasound Diagnostics of the Faculty for Advanced Training & Retraining. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Elena A. Dikareva.

Tweet